

Congrès ESMO 2025

Participation des équipes IUCT-Oncopole

984P - FIPO23: A First-in-Human Trial of XON7, a Glyco-Humanized Polyclonal Antibody (GHpAb) Targeting Multiple Tumor Antigens in Advanced Solid Tumors

Presentation Number 984P / Speakers Jaafar Bennouna (Suresnes, France, CEDEX)

1592eP - Pooled safety analysis of Modified Vaccinia Virus Ankara-based therapeutic vaccine alone or in combination in cancer and cervical intraepithelial neoplasia (CIN) clinical trials.

Presentation Number 1592eP / Speakers Christian H. Ottensmeier (Liverpool, United Kingdom)

214eP - Exploratory Biomarkers evaluation to enhance characterization and explore treatment response prediction in metastatic ovarian cancer patients undergoing therapy with EVT801, a highly selective VEGFR-3 inhibitor

Presentation Number 214eP / Speakers Pierre Fons (Toulouse, France)

515P - Real world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR+/HER2- metastatic breast cancer in the ESME-MBC cohort

Presentation Number 515P / Speakers Romain Varnier (Lyon, France)

526P - Capivasertib plus fulvestrant as first- and second-line endocrine-based therapy in PIK3CA/AKT1/PTEN-altered hormone receptor-positive advanced breast cancer: Subgroup analysis from the Phase 3 CAPitello-291 trial

Presentation Number 526P / Speakers Hope S. Rugo (Los Angeles, United States of America, CA)

618TiP - Phase I/II study of tuvusertib, an ATR inhibitor in combinaison with fulvestrant in hormone receptor-positive and HER2-negative, advanced breast cancers, resistant to CDK4/6 inhibitors plus aromatase inhibitor-based endocrine treatments and in various molecular contexts (MATRIx)

Presentation Number 618TiP / Speakers Arthur Géraud (Marseille, France)

621TiP - BNT323-03: A phase I/II trial of BNT323/DB-1303 (HER2 ADC) with BNT327 (PD-L1 x VEGF-A) in patients (pts) with advanced breast cancer (BC)

Presentation Number 621TiP / Speakers Shanu Modi (New York, United States of America, NY)

628TiP - A phase 2 study of zelenectide pevedotin, a bicycle drug conjugate, in patients with NECTIN4 amplified advanced breast cancer (Duravelo-3)

Presentation Number 628TiP / Speakers Giuseppe Curigliano (Milan, Italy)

587P - Recent nationwide overall survival trends across subtypes in 33,044 patients with metastatic breast cancer in the French ESME cohort

Presentation Number 587P / Speakers Paul H. Cottu (Paris, France)

2137P - ASP2138 monotherapy in patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, advanced solid tumors: Phase I/Ib trial

Presentation Number 2137P / Speakers Kohei Shitara (Kashiwa, Japan, Chiba)

1549P - EXPAND-1, a phase I/II study of ANV600, a PD-1 targeted IL-2R- $\beta\gamma$ agonist, in monotherapy and in combination with pembrolizumab, in advanced solid tumors

Presentation Number 1549P / Speakers Martina Imbimbo (Bellinzona, Switzerland)

1861P : When Toxicity Ends Treatment: Prognostic Impact of ICI Discontinuation in Advanced NSCLC (ESME Cohort).

Gregoire Justeau; Laurence Masse; Coureche Kaderbhai; Maurice Perol; Didier Debieuvre; Lionel Falchero; Anne Madroszyk; Clarisse Audigier Valette; Xavier Quantin; Victoria Ferrari; Christèle Locher; Nicolas Girard; Yannick Le Guen; Frédéric Bigot; Anne Baranzelli; Lise Thibonnier; Karim Amrane; Lise Bosquet; Christos Chouaid; Bastien Cabarrou

1403P : Validation of transcriptomic signatures associated with response or resistance to nivolumab in head and neck squamous cell carcinoma (HNSCC) patients

Bastien Cabarrou, Constance Lamy, Sonia Canjura Rodriguez, Mehdi Lamkhieud, Elodie Girard, Emmanuel Bouilhol, Roger Sun, Eric Deutsch, Marta Jimenez, François Legrand, Séverine Tabone-Eglinge, Anne Schnitzler, Valéry Attignon, Caroline Even, Christophe Le Tourneau, Ellen Van Obberghen-Schilling, Nicolas Servant, Thomas Filleron, Pierre Saintigny, Ivan Bièche

134P : Molecular biomarker analysis in the phase II basket PEVOSq trial testing pembrolizumab with vorinostat on late-stage squamous cell carcinoma supports HDAC inhibition as an immunotherapy enhancer

Miguel Francisco, Gianmaria Frige, Bastien Cabarrou, Zhan Yinxiu, Gabor Balogh, Isabel Brito, Maral Halladjian, Thomas Filleron, Marta Jimenez, François Legrand, Emmanuelle Jeannot, Abderaouf Hamza, Stephan H. Bernhart, Célia Dupain, Edith Borcoman, Maud Kamal, Christophe Le Tourneau, Luca Mazzarella, Nicolas Servant

550P - Retrospective analysis of molecular resistance biomarkers to trastuzumab deruxtecan (T-DXd) in metastatic breast cancer (mBC)

F. Giugliano, Y. Pradat, D. T. N. Tran, B. Pistilli, G. Curigliano, N. Droin, M. Jimenez, M. Lacroix-Triki, M. Deloger, G. Jules-Clement, C. Nicotra, M. Ngocamus, V. Diéras, A. Lusque, E. Bernard, A. Italiano, F. André, F. Mosele.

666MO - Reliability of cerebrospinal fluid (CSF) ctDNA as a surrogate for tumor mutational profiling in central nervous system (CNS) metastases: Results from the BrainStorm (OncoDistinct006) study

Speakers Luca Arecco (Genova, Italy) / Lecture Time 09:35 - 09:40

1706O - Efficacy, safety and subgroup analysis of 177Lu-edotreotide vs everolimus in patients with grade 1 or grade 2 GEP-NETs: Phase III COMPETE trial

Speakers Jaume Capdevila (Barcelona, Spain) / Lecture Time 11:05 - 11:15

3084P - Durvalumab (D) +/- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma (MIBC): Updated results (EFS and OS) of NEMIO, a phase I/II trial

Presentation Number 3084P / Speakers Constance Thibault (Paris, France)

3109eP - Avelumab first-line maintenance (1LM) treatment for advanced urothelial carcinoma (aUC) in France: Conditional survival and long-term safety in patients (pts) treated for ≥ 1 or ≥ 2 yrs in the AVENANCE real-world study

Presentation Number 3109eP / Speakers Constance Thibault (Paris, France)

3111eP - Real-world (RW) use of enfortumab vedotin (EV) in patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) previously treated with chemotherapy and immunotherapy in France

Presentation Number 3111eP / Speakers Aude Flechon (Lyon, France)

1345P - Omission of elective neck irradiation in pT3-T4 oral squamous cell carcinoma with a pN0 neck: Impact on regional control and overall survival

Presentation Number 1345P / Speakers MATHILDE MIRALLIE (Toulouse, France)

1624P - Comparison of patients' clinical outcomes treated with flat dose or weight-adjusted dose of pembrolizumab in advanced melanoma, a multicenter observational study

Presentation Number 1624P / Speakers Iona Campo le Brun (Versailles, France)

1674P - Real-world use of encorafenib + binimetinib in unresectable/metastatic melanoma: Results from the MelBase French database

Presentation Number 1674P / Speakers Celeste Lebbe (Paris, France, CEDEX 10)

1103P - Role of surgery in stage IV high-grade serous ovarian carcinoma: A French population-based multicenter study

Presentation Number 1103P / Speakers Diana Bello Roufai (Paris, France)

1133P - GREAT: Clinical outcomes from a prospective study of 1,456 patients (pts) with advanced ovarian cancer (AOC), including theranostic biomarker analysis (BRCA and genomic instability score) and paired tumor/DNA collection in the PARP inhibitor era

Presentation Number 1133P / Speakers Thibault De La Motte Rouge (Rennes, France)

1161P - Transcriptomic and genomic profiles of chromosomally unstable endometrial tumors: Ancillary analyses of the GINECO UTOLA trial and CARPEM cohort

Presentation Number 1161P / Speakers Juliette Renard (Paris, France)

1239eTiP - BELLA: A phase II study of relacorilant plus nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer

Presentation Number 1239eTiP / Speakers Jae-Weon Kim (Seoul, Republic of Korea)

2773P - Patient-reported outcomes (PROs) from DeLLphi-304: The first phase III trial evaluating tarlatamab and chemotherapy (CTx) in patients (Pts) with previously treated small cell lung cancer (SCLC)

Presentation Number 2773P / Speakers Giannis Mountzios (Athens, Greece)

1996P - Long-term outcomes with tepotinib for clinically relevant subgroups of patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION study: A ≥3-year follow-up

Presentation Number 1996P / Speakers Frank Griesinger (Oldenburg, Germany)

Mini Oral Session - LBA101 - Tarlatamab as second-line (2L) treatment for small cell lung cancer (SCLC): Outcomes by chemotherapy-free interval (CFI) and prior PD-(L)1 inhibitor use in the phase III DeLLphi-304 trial

Speakers Pedro F. Simoes da Rocha (Barcelona, Spain)

Mini-oral presentation : START-001: initial phase 2 clinical activity of invikafusp alfa, a first-in-class T cell receptor (TCR) Beta-chain-targeted bispecific antibody as monotherapy in patients with antigen-rich solid tumors resistant to immune checkpoint blockade (ICB).

A. Italiano, E. Garralda, A. Marabelle, C. Friedman, ...Carlos Gomez-Roca, Zhen Us, Ke Liu, Lilian L Siu, James Gulley.

1550P - Survival Outcomes in a phase I trial combining the STING agonist Ulevostinag ± Pembrolizumab in Solid Tumors (MK1454-001)

S. Llop MD1, P. Jimenez-Labaig MD1,2,3, I. Micheletto MD1, A. Rullan MD PhD4,5, K. Ouali MD PhD6, S. Champiat MD PhD7, B. Etienne MD PhD8, E. Romano MD PhD8, T. Golan MD PhD9, C. Gomez-Roca MD10, R. Perets MD PhD11, D. Wong MD PhD12, K.J. Harrington MBBS PhD1,2

FPN 3759 Mitigating infusion-related reactions (IRRs) with cetirizine and montelukast in patients (pts) receiving REGN7075, an EGFR×CD28 bispecific antibody (bsAb)

Neil H. Segal,¹ Eugenia Girda,² Bridget P. Keenan,³ J. Randolph Hecht,⁴ Xiuning Le,⁵ Melissa Johnson,⁶ Javier Torres-Jiménez,⁷ Carlos Gomez-Roca,⁸ François Ghiringhelli,⁹ Öztürk Ateş,¹⁰ Victor Moreno-García,¹¹ Douglas Laux,¹² David Berz,¹³ Ruifeng Chen,¹⁴ JuAn Wang,¹⁴ Hyunsil Han,¹⁴ Melissa Mathias,¹⁴ Frank A. Seebach,¹⁴ Michael Kinnaman,¹⁴ Davendra Sohal¹⁵

214eP Exploratory biomarkers evaluation to enhance characterization and explore treatment prediction in metastatic ovarian cancer patients undergoing therapy with EVT801, a highly selective VEGFR-3 inhibitor

Pierre Fons, Carlos Gomez-Roca et al

216p MegaMOST – A multicenter, open-label, molecularly selected Bayesian phase II platform trial in advanced or metastatic solid tumors: Final analysis of the trametinib cohort

I.Ray-Coquard; S. Cousin, L. Verlingue,....Carlos Gomez-Roca....

1558P - Mitigating infusion-related reactions (IRRs) with cetirizine and montelukast in patients (pts) receiving REGN7075, an EGFR×CD28 bispecific antibody (bsAb)

Presentation Number 1558P / Speakers Neil H. Segal (New York, United States of America)

2114P - Ramucirumab (Ram) +/- paclitaxel (Pacli) as second-line (L2) therapy in older patients (pts) with advanced esophagogastric adenocarcinomas (EGA): The SOCRATE-PRODIGE 55 randomized phase II study

Presentation Number 2114P / Speakers Astrid Lievre (Rennes, France)

2224P - PRODIGE 29-UCGI 26 (NEOPAN): A phase III randomised trial comparing chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (LAPC). Quality of life assessment results

Presentation Number 2224P / Speakers Michel P. Ducreux (Villejuif, France)

812P - Efficacy and safety of two schemes of nivolumab (Nivo) and ipilimumab (Ipi) in MSI/dMMR metastatic colorectal cancer (mCRC): The PRODIGE-74 GERCOR NIPISAFE randomized non-comparative phase II trial

Presentation Number 812P / Speakers Romain Cohen (Paris, France)

1529P - Impact of severe immuno-related adverse events on survival in deficient mismatch repair/microsatellite instable-high gastro-intestinal (dMMR/MSI-H GI) cancers treated with immune checkpoint inhibitors (ICI)

Presentation Number 1529P

1738eTiP - IMMUNORARE5: A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy (domvanalimab + zimberelimab) in patients with advanced rare cancers: The neuroendocrine tumors cohort

Presentation Number 1738eTiP / Speakers Thomas Walter (Lyon, France)

136P - Nivolpi70: Safety and efficacy of a combination of nivolumab-ipilimumab (Nivlp) in elderly patients (pts) over 70 years old regardless of tumor localization

Presentation Number 136P / Speakers Jeanne Duval (Paris, France)

2817P - Development of a care complexity score to predict severe adverse events (PRO-CTCAE) and resource utilization in remote patient monitoring for oncology: Analysis from 5,625 patients across 86 sites

Presentation Number 2817P / Speakers Maria Alice Franzoi (Villejuif, France)

250eP - Clinical and biological characteristics of a French cohort of cancer of unknown primary with suspected breast origin

Presentation Number 250eP / Speakers Sarah Watson (Paris, France)

3017P - French national multidisciplinary tumor board improves the management and survival of patients with cancer of unknown primary

Presentation Number 3017P / Speakers Sarah Watson (Paris, France)

698P - Clinical, pathological and molecular characteristics of brain metastases from cancer of unknown primary (BM-CUP): A multicenter French retrospective cohort

Presentation Number 698P / Speakers Axel De Bernardi (Lyon, France)

2007P - Tolerance and efficacy of targeted therapies after immunotherapy in metastatic non-small cell lung cancer with molecular alterations: TOXIMAD GFPC 04-2022 study

Presentation Number 2007P / Speakers Thomas Pierret (Bron, France)

2027TiP - Reporos trial-GFPC 04-2023: Open-label phase II efficacy study of repotrectinib in frail patients with ROS1-rearranged metastatic NSCLC

Presentation Number 2027TiP / Speakers Laurent Greillier (Marseille, France)

Mini oral session - LBA76 - Paclitaxel-bevacizumab ± atezolizumab in advanced non-squamous NSCLC progressing after chemo-immunotherapy: IFCT-2201 ADAPTABLE randomized phase II trial

Speakers Etienne Giroux-Leprieur (Boulogne-Billancourt, France)

1123P - Efficacy and safety of pembrolizumab–lenvatinib in metastatic endometrial cancer: Results from the French multicenter early access program (LARENA)

Presentation Number 1123P / Speakers Diana Bello Roufai (Paris, France)

1160P - Immune landscape heterogeneity in endometrial carcinoma: Ancillary analyses of GINECO UTOLA trial and CARPEM cohort

Presentation Number 1160P / Speakers Julie Berthet (Paris, France)

620TiP - HEROES: De-escalation of anti-HER2 therapies in HER2-positive metastatic breast cancer with long-term persistent response and undetectable minimal residual disease in circulating tumor DNA

Presentation Number 620TiP / Speakers Benjamin Verret (Villejuif, France)

2699P - Comprehensive molecular profiling of perivascular epithelioid cell neoplasms

Presentation Number 2699P / Speakers Justine Gantzer (Strasbourg, France, CEDEX)

Mini oral session - 80MO - Durvalumab (D) plus tremelimumab (T) in advanced biliary tract carcinoma (BTC) patients (Pts) after failure of platinum-based chemotherapy (CTx): Final results of the IMMUNOBIL GERCOR D18-1 PRODIGE-57 phase II trial

Speakers Matthieu Delaye (Paris, France)